



## Request for Letters of Intent

### Health Equity Research Grant, Sponsored by GSK

#### 2024 Grantees

#### Purpose

Ovarian Cancer Research Alliance is requesting Letters of Intent for the 2024 Health Equity Research Grant, Sponsored by GSK.

Despite major advances in ovarian cancer research over the past 20 years, addressing health disparities is an area in which significant progress has yet to be made. OCRA believes that every ovarian cancer patient should have the opportunity to attain the best possible care and treatment outcomes, and that their socioeconomic status, geographic location, or racial or ethnic background should not impact the likelihood of reaching those goals. GSK's goal is to make research as representative and accessible as possible. Enhancing understanding of barriers and diversity of patient populations is a critical step towards combatting health care disparities and enabling health equity, a shared commitment of OCRA and GSK. Through this generous sponsorship we are excited to offer a brand-new funding opportunity.

The objective of this grantmaking program is to support projects that promote equity, inclusivity, and evidence-based approaches to overcome the barriers faced by marginalized communities with a focus on ovarian cancers and/or related gynecologic cancers. For the purposes of this grant, marginalized communities are defined as groups that have historically struggled with equal access to care due to gender identity, sexual orientation, race, ethnicity, disability status, and language barriers. We encourage researchers that are from groups underrepresented in sciences to apply, but this is not a requirement of the grant.

Projects may encompass a wide range of research areas, including but not limited to:

- Identifying and addressing social, cultural, and economic factors that contribute to health disparities in ovarian cancer
- Improving access to quality care, diagnostic tools, and treatment options for underserved communities affected by ovarian cancer
- Exploring the impact of racial, ethnic, socioeconomic, or geographic disparities on disease progression and survival rates
- Investigating the genetic and molecular factors influencing ovarian cancer disparities and potential therapeutic approaches

## Eligibility and Selection Criteria

1. Principal Investigators at all stages of their careers are eligible to apply. Applicants must have their PhD, ScD, MD or other doctoral degree at the time of application.
2. The selection committee will consider most favorably applications that are creative, original, with potential for long-term impact in the field and authorship of publications. The proposed projects may be new research projects or may be part of ongoing research.
3. International applicants are welcome to apply.
4. Investigators whose proposed projects do NOT have a health equity research focus in ovarian cancer or other related gynecological cancers are not eligible for this grant.

If you have any questions about your eligibility, please contact us (see last page).

## Terms of Grant

Support of up to \$100,000USD annually for two years (\$200,000 USD total) will be awarded to the institution in which the recipient will conduct the research. The Health Equity Research Grant, Sponsored by GSK will have a start date of March 1, 2024. Grant recipients will be required to submit activation deliverables and annual progress reports (narrative and financial) throughout the life of the grant. Please note the progress reports will be shared with GSK, the sponsor of this grant. It is expected that the project will result in peer-reviewed publication(s). Any publications or presentations of work resulting from this grant should acknowledge support from OCRA and GSK. Additionally, grant recipients can only have one OCRA grant active at a time. If the grant recipient also has another active OCRA grant, the first grant must end before the new may begin.

## Selection Process

Letters of Intent will be reviewed by the distinguished members of the medical, research and patient advocacy community from across North America. The majority of LOIs will be triaged at this stage; only a fraction of those submitting LOIs will be invited to submit full proposals. We recognize that preparing a full application requires a significant amount of time and energy for investigators, and we believe this process will ensure that only those applications most likely to be competitive will advance to the final round of selection.

## Timeline

**The submission deadline for LOIs is 5:00pm Eastern Time (NY) on Tuesday, August 22, 2023.** Late submissions and extension requests are not permitted. All applicants will be notified of their status in late September. Please be sure to add [OCRA@smartsimplemailer.com](mailto:OCRA@smartsimplemailer.com) to your safe sender list in your email so you can get all emails from the system. For those selected to submit full proposals, full proposals will be due mid-October 2023.

## Application Process

Letters of Intent must be submitted in English via the [SmartSimple](https://ocra.us-1.smartsimple.com/) website (<https://ocra.us-1.smartsimple.com/>) by 5:00pm ET on August 22, 2023 by the Principal Investigator. Please be sure to add [OCRA@smartsimplemailer.com](mailto:OCRA@smartsimplemailer.com) to your safe sender list in your email so you can get all emails from the system.

The SmartSimple website is easy to use and will lead you through the completion of the LOI. We recommend you log into the website soon and familiarize yourself with the website as well as the required parts of the LOI.

Beyond basic contact information about yourself (the Principal Investigator) and any key personnel (if applicable), LOIs must include the following:

1. **Scientific Abstract** – Provide an abstract for the scientific community of the proposed research project, which should be presented in 6,000 characters or less (including spaces). Text only; figures, images, and graphs are not permitted.
2. **PI BioSketches** -- A current NIH biosketch for the PI is required. Please use the NIH Biosketch template available for download in SmartSimple and adhere to its instructions and space limitations.
3. **Key Personnel Biosketches** -- NIH biosketches should be provided for anyone you listed in SmartSimple as Key Personnel. All key personnel biosketches should be combined into one document and uploaded as a single PDF. Please use the biosketch template available for download in SmartSimple, and adhere to its instructions and space limitations.
4. **Budget** -- Requested total budget amount for both years in USD. A detailed budget is not required during the LOI; only an estimated total budget request is required at this time.

*No figures, references, appendices, detailed budgets, or letters of recommendation or collaboration are required or accepted at this stage.*

Answers to frequently asked questions about the application process are available online [here](https://ocrahope.org/research/for-grantees/grant-application-faq/) (<https://ocrahope.org/research/for-grantees/grant-application-faq/>).

### Technical Support

If you are having technical problems with SmartSimple please email OCRA – [grants@ocrahope.org](mailto:grants@ocrahope.org). SmartSimple works best when using Google Chrome. Be sure your pop ups are not blocked on your web browser as some items will open a new window.

Questions about the substantive aspects of the application should be directed to Kristin McGowan (contact info below).

### About OCRA

Ovarian Cancer Research Alliance (OCRA) is the leading organization in the world fighting ovarian cancer from all fronts, including in the lab and on Capitol Hill, while supporting women and their families. Visit [ocrahope.org](http://ocrahope.org) to learn more.

#### **For inquiries or further information, please contact:**

Kristin McGowan  
Ovarian Cancer Research Alliance  
Telephone: (212) 268-1002  
E-mail: [grants@ocrahope.org](mailto:grants@ocrahope.org)